[{"orgOrder":0,"company":"Boundless Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"ecDNA-directed therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Boundless Bio","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Boundless Bio \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Boundless Bio \/ Nextech Invest"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BBI-355","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Not Applicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"ecDNA-directed Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Boundless Bio \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Leaps by Bayer"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BBI-825","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless Bio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Boundless Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BBI-825 is an ecDNA-directed therapy, a small molecule inhibitor of ribonucleotide reductase, investigated for locally advanced or metastatic cancer with resistance gene amplifications.

                          Brand Name : BBI-825

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 11, 2024

                          Lead Product(s) : BBI-825

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Proceeds will fund BBI-355, an ecDNA-directed therapy and CHK1 inhibitor, currently in Phase 1/2 trials for oncogene-amplified cancers.

                          Brand Name : BBI-355

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : BBI-355

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Goldman Sachs & Co.

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the collaboration, Eli Lilly will supply CDK4/6 inhibitor Verzenio (abemaciclib) for use in combination with BBI-355, an oral, selective small molecule inhibitor of CHK1, in a clinical trial for locally advanced or metastatic solid tumors with onco...

                          Brand Name : BBI-355

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 19, 2023

                          Lead Product(s) : BBI-355,Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene ampli...

                          Brand Name : BBI-355

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 18, 2023

                          Lead Product(s) : BBI-355,Futibatinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Taiho Oncology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Boundless Bio will use the financing to advance BBI-355, a potentially best-in-class checkpoint kinase 1 inhibitor and the first ecDNA-directed therapy, through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncog...

                          Brand Name : BBI-355

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 16, 2023

                          Lead Product(s) : ecDNA-directed Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Leaps by Bayer

                          Deal Size : $100.0 million

                          Deal Type : Series C Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BBI-355 is a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor and the first extrachromosomal DNA (ecDNA)-directed therapy (ecDTx) designed to treat patients with oncogene amplified cancers.

                          Brand Name : BBI-355

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 09, 2023

                          Lead Product(s) : BBI-355

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDN...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 28, 2021

                          Lead Product(s) : ecDNA-directed therapeutic

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Nextech Invest

                          Deal Size : $105.0 million

                          Deal Type : Series B Financing

                          blank